# OnCo record sana-biotechnology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/sana-biotechnology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "sana-biotechnology" ;
  schema:name "Sana Biotechnology"@en ;
  schema:description "Sana Biotechnology is a hypoimmune cell-therapy company that suspended its oncology allogeneic CAR-T (SC262) in late 2025 and pivoted to type 1 diabetes and in vivo CAR-T (SG293)."@en ;
  schema:url <https://onco.cc/companies/sana-biotechnology/>, <https://sana.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.globenewswire.com/news-release/2026/08/10/3342190/0/en/sana-biotechnology-reports-second-quarter-2026-financial-results-and-business-updates.html> ;
  onco:tag "pivot" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/in-vivo-car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> .